Deal of the Day — limited-time pharmacy picks!
Etibo 250mg tablet

Etibo 250mg tablet

Prescription requiredRx Required

Salt Composition: Lapatinib

Expiry Date: 01/2028

Special offer

Buy at $191.29

$191.29

Inclusive of all taxes

▼

30 Tablet(s) In A Bottle

About The Product

breast cancer


Description

Etibo 250mg tablet is an anticancer medication prescribed b y the doctor to treat Early, Advanced or Metastatic Hormone Receptor Positive (HR+) Breast Cancer in Women often in combination with other medicine.

Etibo 250mg tablet contains Lapitinib that belongs to the class of tyrosine kinase inhibitor drug class. Lapitinib slows or stops the growth and spread of cancer cells.

Common Side Effects

  • Like any other chemical based medication Etibo 250mg tablet also has multiple side effects from mild to severe.
  • If symptoms stay for longer period of time, consult your doctor for remedy. ● Hot Flashes ● Joint Pain ● Fatigue ● Headache ● Nausea ● Swelling of Hand ● Hand Foot Syndromes ● Mouth Sores ● Difficulty in Sleeping ● Vaginal Bleeding and Dryness ● Raised Cholesterol level ● Problem of Heart Risk

Dosage And Administration

  • The dosage of Etibo 250mg tablet should be taken orally without food, on empty stomach.
  • Swallow the whole tablet as it is.
  • Avoid breaking, biting, chewing and crushing of tablet to maintain its efficacy.
  • Dosage may vary based on the treatment, its stage and pateint's overall health.

Mechanism Of Action

Etibo 250mg tablet contains Lapitinib that belongs to the class of tyrosine kinase inhibitor drug class.

Lapitinib blocks the HER2 and EGFR receptors (tyrosine kinases), which slows or stops the growth and spread of cancer cells.

Faqs

Etibo 250mg tablet treats Early, Advanced or Metastatic Hormone Receptor Positive (HR+)

Breast Cancer in Women often in combination with other medicine.

References

• Nolting, M., Schneider-Merck, T., & Trepel, M. (2014).

Lapatinib. Small Molecules in Oncology, 125-143. • D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., & Bianco, R.

(2015). Mechanisms of lapatinib resistance in HER2-driven breast cancer.

Cancer treatment reviews, 41(10), 877-883. • Voigtlaender, M., Schneider-Merck, T., & Trepel, M. (2018).

Lapatinib. Small molecules in oncology, 19-44. • Frankel, C., & Palmieri, F.

M. (2010).

Lapatinib side-effect management. Clinical journal of oncology nursing, 14(2).

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026